Study details
Enrolling now
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
Brigham and Women's Hospital
NCT IDNCT05030545ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
40
Study length
about 4.2 years
Ages
18–85
Locations
1 site in MA
About this study
This trial is testing a treatment to see if it improves heart function in people with primary aldosteronism. This condition causes the body to make too much aldosterone, which can lead to high blood pressure and increase the risk of heart disease. The goal is to determine if blocking aldosterone reduces cardiovascular problems.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Eplerenone
PhasePhase 4
DrugEplerenone
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
eplerenone
Drug routes
oral (Oral Tablet)
Body systems
Cardiology / Heart